Congratulations to the Matterhorn study team. FDA approval independent of PD-L1 status. https://t.co/WPR8h4o4gf

Important data for the W&W community: Even in high-risk LARC (MRF+, EMVI-IV, TD+, lateral LN ≥7 mm), patients achieving CR after TNT show excellent long-term outcomes, supporting organ preservation in this challenging subgroup. • CR: 32.6% • Regrowth: 24% (all salvageable) •

New in JAMA Network Open ! A comprehensive meta-analysis by Petousis et al. (n=4013) demonstrates that first-line PARP inhibitor maintenance after platinum-based chemotherapy significantly improves progression-free survival in advanced epithelial ovarian cancer — especially in

Evolving Landscape of Parenteral Anticancer Therapy–Associated Lung Toxicity: Incidence, Monitoring, and Management DOI: 10.1200/OA-25-00105 🔍 A comprehensive review on anticancer therapy–associated interstitial lung disease (ATCA-ILD) — from classic agents like bleomycin and

RT @uyargalip: 📊 Model-based economic evaluation: Geriatric assessment + management (GAM) vs usual care → Improved QALYs → Lower hospitali…

🚀 #ESMO25 Highlight! The Phase III FORTITUDE-101 trial demonstrates improved short-term survival with bemarituzumab + chemotherapy in FGFR2b-overexpressing gastric and GEJ cancer patients. A new step forward for precision oncology in upper GI malignancies. 💡 🔗 #GastricCancer

🎯 Honored to present two posters at #ESMO25 Berlin! 🇩🇪 🧤 2854P – Neuro Glove: A prospective self-controlled study investigating glove compression as a protective strategy against chemotherapy-induced peripheral neuropathy in women with gynecologic malignancies. 🫁 2865P – LRF

Honored to present our recent studies at #ESMO2025! 🌍 Proud to contribute to 9 different oncology projects this year — integrating AI, digital health, and clinical oncology for better patient outcomes. Excited to continue expanding our multi-center collaborations and AI-driven

Day 2 at #ESMO25 – Berlin 🇩🇪 A truly inspiring session with Dr. Mairéad McNamara and Dr. Banerjee — outstanding talks on advancing patient-centered oncology and translational impact. Grateful for the insightful discussions and the chance to learn from such leading experts. #ESMO

🎬 Kicking off #ESMO25 with excitement! Had the pleasure of sharing my insights in a pre-congress interview. 💬 Presenting a project I’ve been dedicated to for the past two years makes this milestone truly special. 💫 You’re warmly invited to Poster Session 8 on Sunday – 🩺

Dr. Samuel Klempner’s insights on NGS, ADCs, and BiTEs, and Dr. Elizabeth Smyth’s talk on therapeutic resistance truly broadened our horizons today. Grateful for this inspiring session and the chance to capture such a memorable moment at #ESMO2025! 🙏✨ @KlempnerSam @LizzySmyth1

Had the privilege to listen to Dr. Samuel Klempner’s inspiring talk on next-generation therapeutics in gastroesophageal cancers at #ESMO25. Feeling truly fortunate to attend his session — especially as I’ll be joining him in Boston at MGH later this year for a clinical

Proud to share our latest work published in Clinical Colorectal Cancer! 🧠 CINR-AI Study — We developed inflammation-, nutrition-, and sarcopenia-based AI models to predict pathological response after total neoadjuvant therapy (TNT) in locally advanced rectal cancer. Key

Excited to be at ESMO Congress 2025 in Berlin! A perfect convergence of innovation, collaboration, and oncology research excellence. 🔬✨ #ESMO2025 #CancerResearch #OncologyCommunity #ESMO25 #ESMOStories @kbaskurtt @Xesiloglu @tubaugurdr @myESMO

Liver-to-Muscle FDG Ratio and Inflammatory Markers as Prognostic Factors in SCLC - Kadriye Başkurt (@kbaskurtt) @uyargalip @osutcuoglu @Xesiloglu https://t.co/e5SQQMibmu #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #SCLC #LungCancer

RT @Xesiloglu: 📢 Just published! Our new article in Clinical and Translational Oncology highlights the prognostic significance of liver-to-…

📣 Just published! Prognostic significance of liver-to-muscle FDG uptake ratio and inflammatory biomarkers in small cell lung cancer 📊 LRF SUVmean ratio emerged as a novel marker of metabolic frailty and survival. 🧠 A simple PET/CT-derived biomarker with strong prognostic

Grateful to have shared my thoughts at this year’s AVOD (Eurasian Oncology Association) Congress — an inspiring and truly multidisciplinary event bringing together oncologists and researchers from different fields. 🌍 Many thanks to the AVOD team for this wonderful organization,